ClinicalTrials.gg
CompletedNCT00830518Updated May 11, 2018Results posted

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

A Phase 2 interventional study of Alisertib in Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Leukemia, Myeloid, Acute by Takeda — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Takeda.

Enrollment
8th of 13
57 · median 60
Started
2009
with 2 others
Phase 2
3 of 14
none open now
Registered
6th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2009, is one of 3 in phase 2, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 14 studies in Leukemia, Myeloid, Acute by Takeda is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Leukemia, Myeloid, Acute by Takeda as a file.
02

Study summary

This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). This study looked at the antitumor activity in people who received alisertib.

The study enrolled 57 patients. Participants were categorized by disease sub-types AML and MDS. Participants received:

  • Alisertib 50 mg

All participants took alisertib capsules every 12 hours each day for 7 days followed by a 14-day rest period in 21-day cycles for approximately 26 cycles.

This multi-center trial was conducted in North America and France. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. The participant could continue treatment beyond 12 months if it was considered by the Sponsor and the Investigator that they would derive benefit from continued alisertib treatment. Participants had weekly blood work and clinic visits, with disease assessments every 2 cycles (ie. every 6 weeks) up to and including Cycle 16. Reduced visits (every 12 weeks) were conducted for participants tolerating treatment beyond Cycle 16 and for participants off treatment without disease progression.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • High-Grade Myelodysplastic Syndrome

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participants must meet all of the following inclusion criteria:

  1. Male or female participants 18 years or older
  2. Eligible diagnoses:

    • Acute myelogenous leukemia (except acute promyelocytic leukemia [APL]) with > 10% bone marrow or peripheral blood blasts; failed to achieve complete response (CR) or relapse after prior therapy, not candidates for potentially curative treatment. Untreated participants > 60 are eligible if not candidates for standard induction.
    • High-grade myelodysplastic syndrome (MDS), defined by all the following features: International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk; > 10% blasts on bone marrow examination; treatment failure from, or not candidates for, standard therapies including demethylating agents, e.g. azacytidine or decitabine.
  3. performance status 0-2
  4. Female participants:

    • for at least one year
    • Surgically sterile, or
    • If , agree to practice two effective methods of or abstain from heterosexual intercourse.
  5. Male participants:

    • Practice effective barrier contraception to one month after the last dose of study drug, or
    • Abstain from heterosexual intercourse.
  6. Voluntary written consent
  7. Participants on hydroxyurea may be included

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females
  2. Known (HIV) positive or acquired immune deficiency syndrome (AIDS) - related illness
  3. Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the protocol completion
  4. Total > 1.5 × the (ULN)
  5. (ALT) and aspartate aminotransferase (AST) > 2.5 × the ULN. AST, ALT may be elevated to 5 x the ULN if reasonably ascribed to underlying hematological disorder.
  6. Calculated \< 30 mL/minute
  7. Antineoplastic or radiotherapy within 14 days preceding the first dose
  8. Myocardial infarction within 6 months of enrollment or current history of (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
  9. Major surgery 14 days prior to the first dose
  10. Clinically uncontrolled central nervous system (CNS) involvement.
  11. Inability to swallow capsules
  12. History of uncontrolled sleep apnea or conditions that result in excessive daytime sleepiness, such as chronic lung disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Alisertib

    Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).

    Drug: Alisertib

Interventions

  • Alisertib capsules

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (ORR) Based on Investigator's Assessment

    Best ORR is defined as the number of participants with complete remission(CR) or partial remission(PR) assessed by the Investigator using modified AML/MDS International Working Group(IWG) Criteria. AML:CR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, bone marrow blasts(BMB) \<5%, transfusion independent, no extramedullary disease(EMD); CRi=BMB \<5%, transfusion independent, no EMD; PR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, BMB \>50% decrease and 5% to 25%, blasts \<5% with Auer rods; PRi=BMB \>50% decrease and 5% to 25%. MDS:CR=bone marrow: ≤5% myeloblasts with normal maturation, peripheral blood: hemoglobin ≥11 g/dL, platelets ≥100x10\^9/L, neutrophils ≥1.0x10\^9/L, blasts 0%; PR=all CR criteria if abnormal before treatment except: BMB decreased by ≥50% over pretreatment but still \>5%; PRi=BMB decreased by ≥50% over pretreatment but still \>5%; Marrow CR=bone marrow: ≤5% myeloblasts and decrease by ≥50% over pretreatment, peripheral blood hematologic improvement responses noted.

    Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from the date of first study drug administration to the date of first documented progressive disease (PD) or death.

    Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)

  2. Duration of Response (DOR)

    Duration of response is defined as the time from the date of first documentation of a response to the date of first documented PD.

    Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)

  3. Best Overall Hematologic Improvement (HI) Response for Myelodysplastic Syndrome Based on Investigator Assessment

    Best overall HI response is defined as percentage of participants with response as assessed by Investigator based on IWG criteria: 1)Erythroid response (pretreatment,\<11 g/dL): hemoglobin (Hgb) increase by ≥1.5 g/dL, relevant reduction of units of red blood cell (RBC) transfusions by absolute number of at least 4 RBC transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks. Only RBC transfusions given for Hgb of ≤9.0 g/dL pretreatment will count in RBC transfusion response evaluation. 2)Platelet response (pretreatment,\<100x10\^9/L):Absolute increase of ≥30x10\^9/L for participants starting-\>20x10\^9/L platelets, increase \<20x10\^9/L to \>20x10\^9/L by at least 100%. 3)Neutrophil response (pretreatment,\<1.0x10\^9/L):At least 100% increase and an absolute increase \>0.5x10\^9/L. 4)Progression or relapse after HI:At least 1 of following: 50% decrement from maximum response levels in granulocytes or platelets, or reduction in Hgb by ≥1.5 g/dL, or transfusion dependence.

    Time frame: Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)

  4. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug was determined by the Investigator.

    Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)

  5. Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

    Vital signs measurements (blood pressure, heart rate, and oral temperature) were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)

  6. Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

    Abnormal Laboratory Values for Chemistry or Hematology tests that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of study drug to 30 days after last dose (Up to 18.9 months)

07

Results

Posted May 11, 2018

Participant flow

Participants took part in the study at 19 investigative sites in France, Canada and the United States from 10 February 2009 to 04 July 2011.

Participant flow — Overall Study
MilestoneAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Started4611
Completed00
Not completed4611
Withdrew: Progressive disease188
Withdrew: Symptomatic deterioration41
Withdrew: Adverse event141
Withdrew: Withdrawal by patient20
Withdrew: Reason not specified81

Outcome measures

PrimaryBest Overall Response Rate (ORR) Based on Investigator's Assessment

Best ORR is defined as the number of participants with complete remission(CR) or partial remission(PR) assessed by the Investigator using modified AML/MDS International Working Group(IWG) Criteria. AML:CR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, bone marrow blasts(BMB) \<5%, transfusion independent, no extramedullary disease(EMD); CRi=BMB \<5%, transfusion independent, no EMD; PR=neutrophils \>1x10\^9/L, platelets \>100x10\^9/L, BMB \>50% decrease and 5% to 25%, blasts \<5% with Auer rods; PRi=BMB \>50% decrease and 5% to 25%. MDS:CR=bone marrow: ≤5% myeloblasts with normal maturation, peripheral blood: hemoglobin ≥11 g/dL, platelets ≥100x10\^9/L, neutrophils ≥1.0x10\^9/L, blasts 0%; PR=all CR criteria if abnormal before treatment except: BMB decreased by ≥50% over pretreatment but still \>5%; PRi=BMB decreased by ≥50% over pretreatment but still \>5%; Marrow CR=bone marrow: ≤5% myeloblasts and decrease by ≥50% over pretreatment, peripheral blood hematologic improvement responses noted.

Time frame:
Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Reported as:
Number · participants
Best Overall Response Rate (ORR) Based on Investigator's Assessment
participantsAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
CR + PR60
Complete Remission (CR + CRi + Marrow CRi)10
Partial Remission (PR + PRi)50
Stable Disease as Best Response172
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of first study drug administration to the date of first documented progressive disease (PD) or death.

Time frame:
Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Reported as:
Median · days
Progression Free Survival (PFS)
daysAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Progression Free Survival (PFS)55.0 (47.0 to 67.0)38.0 (35.0 to 113.0)
SecondaryDuration of Response (DOR)

Duration of response is defined as the time from the date of first documentation of a response to the date of first documented PD.

Time frame:
Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Reported as:
Median · days
Duration of Response (DOR)
daysAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Duration of Response (DOR)409.0 (57.0 to 596.0)—
SecondaryBest Overall Hematologic Improvement (HI) Response for Myelodysplastic Syndrome Based on Investigator Assessment

Best overall HI response is defined as percentage of participants with response as assessed by Investigator based on IWG criteria: 1)Erythroid response (pretreatment,\<11 g/dL): hemoglobin (Hgb) increase by ≥1.5 g/dL, relevant reduction of units of red blood cell (RBC) transfusions by absolute number of at least 4 RBC transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks. Only RBC transfusions given for Hgb of ≤9.0 g/dL pretreatment will count in RBC transfusion response evaluation. 2)Platelet response (pretreatment,\<100x10\^9/L):Absolute increase of ≥30x10\^9/L for participants starting-\>20x10\^9/L platelets, increase \<20x10\^9/L to \>20x10\^9/L by at least 100%. 3)Neutrophil response (pretreatment,\<1.0x10\^9/L):At least 100% increase and an absolute increase \>0.5x10\^9/L. 4)Progression or relapse after HI:At least 1 of following: 50% decrement from maximum response levels in granulocytes or platelets, or reduction in Hgb by ≥1.5 g/dL, or transfusion dependence.

Time frame:
Baseline and every 2 cycles up to Cycle 16 (up to Month 12), from Cycle 17 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Approximately 2.4 years)
Reported as:
Number · percentage of participants
Best Overall Hematologic Improvement (HI) Response for Myelodysplastic Syndrome Based on Investigator Assessment
percentage of participantsAlisertib 50 mg (Myelodysplastic Syndrome)
Erythroid Response0
Platelet Response0
Neutrophil Response0
Progression or Relapse0
Not Available91
Unable to Assess9
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug was determined by the Investigator.

Time frame:
First dose of study drug to 30 days after last dose (Up to 18.9 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths
participantsAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
AE4611
SAE368
Deaths202
SecondaryNumber of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

Vital signs measurements (blood pressure, heart rate, and oral temperature) were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of study drug to 30 days after last dose (Up to 18.9 months)
Reported as:
Number · participants
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Dyspnoea122
Pyrexia102
Hypotension80
Atrial fibrillation41
Tachycardia30
Dyspnoea exertional21
Hypertension11
Supraventricular tachycardia20
Weight decreased20
Tachypnoea10
Hyperthermia10
Hypothermia10
Bradycardia01
Ventricular tachycardia10
SecondaryNumber of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

Abnormal Laboratory Values for Chemistry or Hematology tests that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. A treatment--emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of study drug to 30 days after last dose (Up to 18.9 months)
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Febrile neutropenia174
Anaemia143
Thrombocytopenia92
Neutropenia53
Leukopenia32
Hypoalbuminaemia40
Leukocytosis30
Hypokalaemia30
Hyponatraemia30
Neutrophil count decreased30
Hypocalcaemia20
Clostridium difficile colitis20
Febrile bone marrow aplasia10
Hypoxia10
Hyperkalaemia10
Hypernatraemia10
Hyperglycaemia10
Hypoglycaemia10
Hypomagnesaemia01
Hypophospataemia10
Alanine aminotransferase increased01
Blood bilirubin increased10
Oxygen saturation decreased10
Blood culture positive10
Blood magnesium decreased10
Blood creatinine increased10
White blood cell count decreased10
Gilbert's syndrome10
Lymphoedema10
Platelet count decreased10

Adverse events

Collected over First dose of study drug to 30 days after last dose (Up to 18.9 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 50 mg (Acute Myeloid Leukemia)—36/46 (78.3%)45/46 (97.8%)
Alisertib 50 mg (Myelodysplastic Syndrome)—8/11 (72.7%)11/11 (100%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
Febrile neutropeniaBlood and lymphatic system disorders13/464/11
SepsisInfections and infestations5/462/11
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/460/11
Disease progressionGeneral disorders4/461/11
DyspnoeaRespiratory, thoracic and mediastinal disorders2/461/11
StomatitisGastrointestinal disorders2/461/11
BacteraemiaInfections and infestations1/461/11
Bacterial infectionInfections and infestations1/461/11
FatigueGeneral disorders1/461/11
Multi-organ failureGeneral disorders0/461/11
Most frequent other events
Showing 10 of 91
Most frequent other events
EventAlisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)
DiarrhoeaGastrointestinal disorders21/462/11
FatigueGeneral disorders15/465/11
NauseaGastrointestinal disorders19/463/11
StomatitisGastrointestinal disorders13/464/11
AlopeciaSkin and subcutaneous tissue disorders7/464/11
CoughRespiratory, thoracic and mediastinal disorders9/463/11
EpistaxisRespiratory, thoracic and mediastinal disorders5/463/11
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/463/11
AnaemiaBlood and lymphatic system disorders10/463/11
NeutropeniaBlood and lymphatic system disorders5/463/11

Baseline characteristics

Safety population was defined as all participants who received any amount of alisertib.

Age, Continuous
Age, Continuous(years)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
Mean71.9 ± 7.4169.5 ± 12.5071.4 ± 8.54
Age, Customized
Age, Customized(participants)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
<60 years426
≥60 years42951
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
Female22325
Male24832
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
Hispanic or Latino202
Not Hispanic or Latino34943
Not Reported10212
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
White361046
Black or African American303
Asian101
Not Reported617
Region of Enrollment
Region of Enrollment(participants)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
United States33942
France11213
Canada202
Height
Height(cm)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
Mean165.8 ± 8.35171.4 ± 9.98167.0 ± 8.93
Weight
Weight(kg)Alisertib 50 mg (Acute Myeloid Leukemia)Alisertib 50 mg (Myelodysplastic Syndrome)Total
Mean73.7 ± 13.8080.4 ± 17.2775.0 ± 14.62

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Hematology and Oncology Associates of Northern New Jersey
    Morristown, New Jersey 07962, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Feb 2010, 11 months.

Results were first posted in May 2018, 8 years 3 months after primary completion. A results delay was requested in Jan 2012.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 11 months is below that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2009
First posted
Jan 28, 2009
StartActual
Feb 10, 2009
Primary completionActual
Feb 2, 2010
CompletionActual
Jul 4, 2011
Results delay requested
Jan 26, 2012
Results first posted
May 11, 2018
Last update
May 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00830518
Responsible party
Sponsor
First posted
Jan 28, 2009
Start date
Feb 10, 2009
Primary completion
Feb 2, 2010
Completion
Jul 4, 2011
Results posted
May 11, 2018
Last update
May 11, 2018

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion